Herein, we demonstrated that the quantification of CP and FT coupled to specific expressions of some inflammatory and neurotrophic mediators can be possible in ocular fluids and sediments in a non-invasive manner, and can be used in association with OCT imaging and coupled to routine tests for AD diagnosis. This evidence concerns the gene CP and Alzheimer disease.